Randomized Multicenter Trial of Hyperthermic Isolated Limb Perfusion With Melphalan Alone Compared With Melphalan Plus Tumor Necrosis Factor: American College of Surgeons Oncology Group Trial Z0020

Cornett, Wendy R.; McCall, Linda; Petersen, Rebecca P.; Ross, Merrick I.; Briele, Henry A.; Noyes, R. Dirk; Sussman, Jeffrey J.; Kraybill, William G.; Kane, John M.; Alexander, H. Richard; Lee, Jeffrey E.; Mansfield, Paul F.; Pingpank, James F.; Winchester, David J.; White, Richard L.; Chadaram, Vijaya; Herndon, James E.; Fraker, Douglas L.; Tyler, Douglas S.

doi:10.1200/jco.2005.05.5152

Cited by 204 publications

(115 citation statements)

References 18 publications

Supporting

Mentioning

101

Contrasting

Unclassified

Order By: Relevance

“…19,20 The more aggressive therapy, HILP, which requires the surgical isolation of the vessels to be cannulated with higher doses of chemotherapy circulated throughout the extremity, results in complete response rates between 40% and 80%. 8,[21][22][23][24][25][26] The complete response rates in our cohort are similar to these other single-center studies, with complete responses in 30% of patients undergoing an ILI and in 44% of patients receiving an HILP. However, in our study, the rate of progressive disease, defined by the modified Response Evaluation Criteria in Solid Tumors 6 as an increase in size of a preexisting lesion by 20% or the appearance of a new lesion within 12 weeks of regional therapy, was 32% for the ILI cohort and 11% for HILP cohort.…”

Section: Commentsupporting

confidence: 72%

Predicting Disease Progression After Regional Therapy for In-Transit Melanoma

Lidsky

Turley

Beasley

et al. 2012

Journal of Surgical Research

View full text Add to dashboard Cite

Section: Commentsupporting

confidence: 72%

Predicting Disease Progression After Regional Therapy for In-Transit Melanoma

Lidsky

Turley

Beasley

et al. 2012

Journal of Surgical Research

View full text Add to dashboard Cite

“…Response rates for ILP with melphalan alone was lower than for melphalan and rhTNF alpha combined (46 % vs. 69 %). In a randomized trial comparing ILP with melphalan alone to ILP with melphalan and rhTNF alpha [439], no significant benefit was detected for combination therapy. However, the trial was aborted at the behest of the DSMB.…”

Section: Clinical Aspects With Regard To Indicationmentioning

confidence: 99%

Malignant Melanoma S3‐Guideline “Diagnosis, Therapy and Follow‐up of Melanoma”

Pflugfelder

Kochs

Blum

et al. 2013

J Deutsche Derma Gesell

180

148

View full text Add to dashboard Cite

“…For example, a prospective randomized clinical trial directly comparing hyperthermic ILP with single-agent melphalan to combination melphalan and TNF-alfa did not show a significant difference in response rate. 162 TNF-alfa is currently unavailable for use in the United States.…”

Section: Regional Therapy: Isolated Limb Perfusion and Infusionmentioning

confidence: 99%

Melanoma, Version 2.2016, NCCN Clinical Practice Guidelines in Oncology

Coit¹,

Thompson²,

Algazi³

et al. 2016

J Natl Compr Canc Netw

Self Cite

218

167

View full text Add to dashboard Cite

OverviewIn 2016, an estimated 76,380 patients will be diagnosed with and approximately 10,130 patients will die of melanoma in the United States.1 However, these figures for new cases may represent a substantial underestimate, as many superficial and in situ melanomas treated in the outpatient setting are not reported. The incidence of melanoma continues to increase dramatically, at an overall rate of 33% for men and 23% women from 2002 to 2006.2 Melanoma is increasing in men more rapidly than any other malignancy, and in women more rapidly than any other malignancy except lung cancer. AbstractThis selection from the NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines) for Melanoma focuses on adjuvant therapy and treatment of in-transit disease, because substantial changes were made to the recommendations for the 2016 update. Depending on the stage of the disease, options for adjuvant therapy now include biochemotherapy and highdose ipilimumab. Treatment options for in-transit disease now include intralesional injection with talimogene laherparepvec (T-VEC), a new immunotherapy. These additions prompted reassessment of the data supporting older recommended treatment options for adjuvant therapy and in-transit disease, resulting in extensive revisions to the supporting discussion sections. J Natl Compr Canc Netw 2016;14(4):450-473 NCCN Categories of Evidence and ConsensusCategory 1: Based upon high-level evidence, there is uniform NCCN consensus that the intervention is appropriate. Category 2A: Based upon lower-level evidence, there is uniform NCCN consensus that the intervention is appropriate. Category 2B: Based upon lower-level evidence, there is NCCN consensus that the intervention is appropriate. Category 3: Based upon any level of evidence, there is major NCCN disagreement that the intervention is appropriate.All recommendations are category 2A unless otherwise noted.Clinical trials: NCCN believes that the best management for any cancer patient is in a clinical trial. Participation in clinical trials is especially encouraged. Please NoteThe NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines ® ) are a statement of consensus of the authors regarding their views of currently accepted approaches to treatment. Any clinician seeking to apply or consult the NCCN Guidelines ® is expected to use independent medical judgment in the context of individual clinical circumstances to determine any patient's care or treatment. The National Comprehensive Cancer Network ® (NCCN ® ) makes no representation or warranties of any kind regarding their content, use, or application and disclaims any responsibility for their applications or use in any way. The full NCCN Guidelines for Melanoma are not printed in this issue of JNCCN but can be accessed online at NCCN.org.© National Comprehensive Cancer Network, Inc. 2016, All rights reserved. The NCCN Guidelines and the illustrations herein may not be reproduced in any form without the express written permission of NCCN. Disclosures for the NCCN Melanoma ...

show abstract

Randomized Multicenter Trial of Hyperthermic Isolated Limb Perfusion With Melphalan Alone Compared With Melphalan Plus Tumor Necrosis Factor: American College of Surgeons Oncology Group Trial Z0020

Cited by 204 publications

References 18 publications

Predicting Disease Progression After Regional Therapy for In-Transit Melanoma

Predicting Disease Progression After Regional Therapy for In-Transit Melanoma

Malignant Melanoma S3‐Guideline “Diagnosis, Therapy and Follow‐up of Melanoma”

Melanoma, Version 2.2016, NCCN Clinical Practice Guidelines in Oncology

Contact Info

Product

Resources

About